Inotek Pharmaceuticals Corp. (extinct)

Inotek Pharmaceuticals Corp. (extinct)

Inotek Pharmaceuticals Corp. (extinct)

Overview
Date Founded

1999

Headquarters

91 Hartwell Avenue,2nd floor,Lexington, MA 02421

Type of Company

Public

Employees (Worldwide)

17

Industries

Pharmaceuticals
IT Consulting & Services
Retail: Drug Stores
Medical Support Services
Biotechnology

Company Description

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Contact Data
Trying to get in touch with decision makers at Inotek Pharmaceuticals Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Business Officer & Executive Vice President

Paths to Inotek Pharmaceuticals Corp.
Potential Connections via
Relationship Science
You
Inotek Pharmaceuticals Corp.
Recent Transactions
Details Hidden

Inotek Pharmaceuticals Corp. purchases Rocket Pharmaceuticals Ltd. resulting in a new company Rocket Pharmaceuticals, Inc.

Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Transaction Advisors
Escrow Agent

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Underwriter

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Underwriter

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Chair, Life Sciences Practice

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Key Stats and Financials As of
Market Capitalization
$590M
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

Founded in 1965, Caisse de Dépôt et Placement du Québec is one of the largest institutional fund managers in Canada and North America. They are the leading private equity investor in Canada and are also one of largest real estate asset managers in the world. The Caisse is headquartered in Québec, Canada.

Details Hidden

Rho Capital Partners is the parent company to Rho’s three operating divisions, Rho Ventures, Rho Canada Ventures and Rho Fund Investors. Founded in 1981, Rho began its private equity activities as a family investment office. Today, Rho is a leading private equity firm that manages a series of funds, under each of its three divisions, backed by a broad group of institutional investors that include endowments, foundations, families, pension funds, and other financial institutions. Across all of Rho’s activities and strategies, our teams are committed to investing in growth and building companies over the long-term. Unique among private equity firms, Rho’s three divisions are each managed by dedicated teams who invest separate funds, yet all benefit from actively cross-leveraging other divisions’ networks to generate differentiated perspectives and insights.

Details Hidden

Rho Ventures focuses on investments in the information technology, communications, new media, healthcare and energy technology sectors. The firm invests across all stages of a company's development from seed to growth equity rounds. Rho Ventures usually acts as lead investor. The firm looks for companies with: (1) outstanding entrepreneurial management teams capable of building exceptional companies (2) growing markets with the potential to produce revenue greater than $500 million (3) market-leading positions with a high level of product/service differentiation (4) well-defined customer value propositions (5) high barriers to competitive entry and (6) scalable and well-defined business models

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Inotek Pharmaceuticals Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Inotek Pharmaceuticals Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Inotek Pharmaceuticals Corp..